Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Completed Phase 4 Trials for Flu caused by Influenza / Orthomyxoviridae Infections Prevention

IndicationsStatusPurposePhase
CompletedPrevention4
clinicaltrials.gov IdentifierTitleDrugs
NCT03617523Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
NCT03546192Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
NCT03308825Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
NCT02908269Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
NCT02915302Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
NCT02563093Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
NCT02539108Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
NCT02258334Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
NCT02222870Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
NCT01946425Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
NCT01946438Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
NCT01720277High Dose Influenza Vaccine in Nursing Home - Pilot Study
NCT01691339Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
NCT01691326Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
NCT01427309A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
NCT01430819Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
NCT00831987Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
NCT00836953Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
NCT00835926A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
NCT00831675Study of Safety and Immunogenicity of Fluzone® in Healthy Children
NCT00812110Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
NCT00735475A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
NCT00755274Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®
NCT00743275A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
NCT00561002Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine
NCT00538512Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4
NCT00389857Trial to Collect Safety Data and Sera for Immunogenicity Testing
NCT00389532Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine
NCT00390884Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
NCT00258830Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
NCT00258817Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
NCT00138294Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
NCT00138281Influenza Immunity Against Pandemic Respiratory Virus
NCT00138385Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment
NCT00133510Influenza Vaccine in Pediatric Transplant Subjects